| Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. | |
| | |
MedLine Citation:
|
PMID: 14638544 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The inflammatory/antiinflammatory properties of HDL were compared with HDL cholesterol in 2 groups of patients and in age- and sex-matched control subjects. METHODS AND RESULTS: Group 1 consisted of 26 patients not yet taking a statin who presented with coronary heart disease (CHD) or CHD equivalents by National Cholesterol Education Program Adult Treatment Panel III criteria studied before and 6 weeks after 40 mg/d of simvastatin. Group 2 consisted of 20 patients with documented CHD and HDL cholesterol > or =84 mg/dL. The inflammatory/antiinflammatory properties of HDL were determined by the ability of the subject's HDL to alter LDL-induced monocyte chemotactic activity (MCA) in a human artery wall coculture. Induction of MCA by a control LDL was determined in the absence or presence of the subject's HDL. Values in the absence of HDL were normalized to 1.0. Values >1.0 after the addition of HDL indicated proinflammatory HDL; values <1.0 indicated antiinflammatory HDL. Group 1 values before simvastatin were LDL cholesterol, 118+/-24 mg/dL; HDL cholesterol, 57+/-13 mg/dL; triglycerides, 125+/-64 mg/dL; and high-sensitivity C-reactive protein (hs-CRP), 1.7+/-1.9 mg/L; and MCA values were 1.38+/-0.91, compared with 0.38+/-0.14 for control subjects (P=1.5x10(-5)). After simvastatin, values were LDL cholesterol, 73+/-24 mg/dL; HDL cholesterol, 61+/-14 mg/dL; triglycerides, 99+/-52 mg/dL; and hs-CRP, 1.3+/-1.3 mg/L; and MCA values were 1.08+/-0.71. In group 2, values were LDL cholesterol, 108+/-34 mg/dL; HDL cholesterol, 95+/-14 mg/dL; triglycerides, 89+/-44 mg/dL; and hs-CRP, 0.8+/-0.7 mg/L; and MCA values were 1.28+/-0.29, compared with 0.35+/-0.11 for control subjects (P=1.7x10(-14)). Similar results were obtained with the cell-free assay. CONCLUSIONS: The inflammatory/antiinflammatory properties of HDL distinguished patients from control subjects better than HDL cholesterol and were improved with simvastatin. |
| | |
Authors:
|
Benjamin J Ansell; Mohamad Navab; Susan Hama; Naeimeh Kamranpour; Gregg Fonarow; Greg Hough; Shirin Rahmani; Rachel Mottahedeh; Ravi Dave; Srinivasa T Reddy; Alan M Fogelman |
Related Documents
:
|
7585284 - Role of dietary cholesterol in the optimal diet for the treatment of hypercholesterolemia. 15163474 - The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes. 9081694 - Lipoprotein lipid response to the national cholesterol education program step ii diet b... 19999214 - Inherited dyslipidaemic disorders contributing to coronary heart disease. 22536284 - Ethanolic extract of vitis thunbergii exhibits lipid lowering properties via modulation... 7315784 - Grading body fatness from limited anthropometric data. |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. Date: 2003-11-24 |
Journal Detail:
|
Title: Circulation Volume: 108 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2003-12-05 Completed Date: 2004-01-09 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 2751-6 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095-1679, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antilipemic Agents / therapeutic use C-Reactive Protein / analysis Chemotaxis / drug effects Cholesterol, HDL / blood, immunology* Cholesterol, LDL / blood, pharmacology Coculture Techniques Coronary Disease / blood, drug therapy* Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Inflammation / blood, immunology* Lipids / blood Lipoproteins, HDL / blood, immunology*, pharmacology Male Middle Aged Monocytes / cytology, drug effects, immunology Predictive Value of Tests Simvastatin / therapeutic use* Treatment Outcome Triglycerides / blood |
| Grant Support | |
ID/Acronym/Agency:
|
HL-30568/HL/NHLBI NIH HHS; RR-00865/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 0/Lipoproteins, HDL; 0/Triglycerides; 79902-63-9/Simvastatin; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Noninvasive evaluation of coronary reperfusion by transthoracic Doppler echocardiography in patients...
Next Document: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarc...